Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis : a European routine-care observational study
(2024) In RMD Open 10(3).- Abstract
Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries. Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0–10), for example, pain ≤2/ Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated. Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by... (More)
Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries. Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0–10), for example, pain ≤2/ Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated. Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/ adjusted for multiple confounders). Results Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar. During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%). However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates. Conclusion Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.
(Less)
- author
- organization
- publishing date
- 2024-07
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Ankylosing, Epidemiology, Pain, Patient Reported Outcome Measures, Spondylitis, Therapeutics
- in
- RMD Open
- volume
- 10
- issue
- 3
- article number
- e004166
- publisher
- BMJ Publishing Group
- external identifiers
-
- scopus:85199661747
- pmid:39053949
- ISSN
- 2056-5933
- DOI
- 10.1136/rmdopen-2024-004166
- language
- English
- LU publication?
- yes
- id
- 5e00cf02-1243-4d25-bb46-3a0840858a01
- date added to LUP
- 2024-09-23 12:27:19
- date last changed
- 2024-09-24 03:00:10
@article{5e00cf02-1243-4d25-bb46-3a0840858a01,
abstract = {{<p>Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries. Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0–10), for example, pain ≤2/ Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated. Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/ adjusted for multiple confounders). Results Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar. During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%). However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates. Conclusion Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.</p>}},
author = {{Christiansen, Sara Nysom and Rasmussen, Simon Horskjær and Ostergaard, Mikkel and Pons, Marion and Michelsen, Brigitte and Pavelka, Karel and Codreanu, Catalin and Ciurea, Adrian and Glintborg, Bente and Santos, Maria Jose and Sari, Ismail and Rotar, Ziga and Gudbjornsson, Bjorn and Macfarlane, Gary J. and Relas, Heikki and Iannone, Florenzo and Laas, Karin and Wallman, Johan K. and van de Sande, Marleen and Provan, Sella Aarrestad and Castrejon, Isabel and Zavada, Jakub and Mogosan, Corina and Nissen, Michael J. and Loft, Anne Gitte and Barcelos, Anabela and Erez, Yesim and Pirkmajer, Katja Perdan and Grondal, Gerdur and Jones, Gareth T. and Hokkanen, Anna Mari and Chimenti, Maria Sole and Vorobjov, Sigrid and Giuseppe, Daniela Di and Kvien, Tore K. and Otero-Varela, Lucia and van der Horst-Bruinsma, Irene and Hetland, Merete Lund and Ørnbjerg, Lykke Midtbøll}},
issn = {{2056-5933}},
keywords = {{Ankylosing; Epidemiology; Pain; Patient Reported Outcome Measures; Spondylitis; Therapeutics}},
language = {{eng}},
number = {{3}},
publisher = {{BMJ Publishing Group}},
series = {{RMD Open}},
title = {{Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis : a European routine-care observational study}},
url = {{http://dx.doi.org/10.1136/rmdopen-2024-004166}},
doi = {{10.1136/rmdopen-2024-004166}},
volume = {{10}},
year = {{2024}},
}